PSMA-targeted radioligand therapy

This page covers all PSMA-targeted radioligand therapy drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting PSMA (prostate-specific membrane antigen).

Targets

PSMA (prostate-specific membrane antigen)

Phase 3 pipeline (1)

• 177Lu-TLX591 · Telix Pharmaceuticals (Innovations) Pty Limited · Oncology
  177Lu-TLX591 is a lutetium-177 labeled radioligand that targets prostate-specific membrane antigen (PSMA) on prostate cancer cells to deliver targeted radiotherapy.

Patent intelligence

• psma targeted radioligand therapy patent landscape — aggregated cliff calendar, attackable patents, originator estates